Abstract:Over 90% of venous thromboembolism (VTE) in children are provoked by transient risk factors and are associated with a very low risk for recurrence (∼1%).[1] Nevertheless, children with a history of VTE and persistent prothrombotic risk factors such as, but not limited to, central venous catheters (CVCs), thrombophilia, and cancer, have an increased risk for recurrent VTE,[2] [3] [4] [5] ranging from 16 to 29% in previous studies.[3] [4] [5] [6] [7] [8] Prospective multicenter data on the use of secondary anticoagulation in patients with a first provoked VTE and persistent or recurrent risk factors are limited. The objective of this study was to characterize secondary anticoagulation use and clinical outcomes in children < 21 years old with provoked VTE. We conducted a secondary analysis of the National Institutes of Health (NIH)-sponsored, multinational Kids-DOTT parallel-cohort randomized controlled trial (RCT; NCT00687882)[1] on duration of anticoagulation for the treatment of acute provoked VTE in patients < 21 years old. The trial was approved by the local institutional review board or research ethics committee at each of the 42 participating sites in Australia, Austria, Canada, the Netherlands, and the United States. The Kids-DOTT trial enrolled 532 children ages 0 to <21 years with a first provoked VTE from 2008 to 2021. Full details of the trial design and eligibility criteria have been previously published.[1] The trial protocol permitted the use of secondary anticoagulation at prophylactic dosing at the discretion of the treating clinician for persistent prothrombotic risk factors following the randomized duration of primary anticoagulation ("extended secondary anticoagulation") or for episodes of transient recurrence of prothrombotic risk factors over the course of the 2-year follow-up period ("episodic secondary anticoagulation"). For this study, we defined extended secondary anticoagulation as any continuation of anticoagulation after the completion of primary anticoagulation treatment. Episodic secondary anticoagulation was defined as anticoagulation that began ≥ 2 weeks after primary anticoagulation was completed. We reviewed all anticoagulant treatment case report forms and extracted details specific to secondary anticoagulant use. Data were summarized as counts and percentages for categorical variables and medians with interquartile ranges (IQR) for continuous variables. To compare groups who did, versus who did not, receive secondary anticoagulation, Mann–Whitney U test was used for continuous variables and chi-square or Fisher's exact test for categorical variables. A p- value of ≤0.05 was considered significant. Statistical analyses were performed using R version 4.1.2 (R Core Team, 2021) and SAS software version 9.4 (Cary, NC). Among 532 participants enrolled in the Kids-DOTT parallel-cohort RCT, 13 (2.4%) were prescribed secondary anticoagulation. Characteristics of participants who did versus did not receive secondary anticoagulation are shown in [Table 1]. Participants who received secondary anticoagulation were older than those who did not (median: 12.8 years [IQR: 7.5–14.18] vs. 7.84 years [0.95–15.1], p = 0.3), but the difference was not statistically significant. Sex, race, and ethnicity did not differ significantly between groups. Variable Overall N = 532[a] No secondary anticoagulation N = 519[a] Secondary anticoagulation N = 13[a] p -Value[b] Age (y) 0.3 Mean 8.26 8.2 10.6 Median (IQR) 7.97 (0.02–20.91) 7.84 (0.95–15.1) 12.77 (7.5–14.18) Sex 0.96 Female 249 (47%) 243 (47%) 6 (46%) Male 283 (53%) 276 (53%) 7 (54%) Race 0.48 American Indian or Alaskan Native 2 (0.4%) 2 (0.4%) 0 (0%) Asian 16 (3.0%) 16 (3.1%) 0 (0%) Black or African American 69 (13%) 68 (13%) 1 (8%) White or Caucasian 385 (72%) 374 (73%) 11(85%) Multiple 5 (9%) 4 (1%) 1 (8%) Other 14 (2.4%) 14 (3%) 0 (0%) Unknown/not reported 41 (7.7%) 41(8%) 0 (11%) Index VTE anatomical site 0.01 Cerebral sinovenous thrombosis 75 (14%) 73 (14%) 2 (15%) 0.70 Lower extremity DVT ± PE 242 (45%) 240 (46%) 2 (15%) 0.04 Renal vein thrombosis 2 (0.4%) 1 (0.2%) 1(8%) 0.05 Right atrial thrombosis 2 (0.4%) 2 (0.4%) 0 (0%) 1.00 Splanchnic vein thrombosis 7 (13%) 6 (1%) 1(8%) 0.16 Upper extremity DVT ± PE 157 (30%) 150 (29%) 7 (54%) 0.07 Other VTE site 46 (9%) 46 (9%) 0 (0%) 0.62 Not reported 1(0.2%) 1 (0.2%) 0 (0%) 1.00 Provoking factor for index VTE Central venous catheter 237 (44%) 229 (49%) 8 (73%) 0.22 Infection 145 (27%) 141 (27%) 4 (31%) 0.69 Trauma or surgery within previous 30 d 92 (17%) 90 (17%) 2 (15%) 0.65 Unspecified 52 (10%) 52 (10%) 0(0%) 0.29 Other 48 (9%) 47 (9%) 1 (8%) -Abstract Truncated-

In Children with Provoked Venous Thromboembolism, Increasing Plasma Coagulability during the First 3 Months Postdiagnosis is Prognostic of Recurrence

Markers of coagulation activation, inflammation and fibrinolysis as predictors of poor outcomes after pediatric venous thromboembolism: A systematic review and meta-analysis

Markers of hypercoagulability in children with newly diagnosed acute lymphoblastic leukemia

Thrombophilia states and markers of coagulation activation in the prediction of pediatric venous thromboembolic outcomes: a comparative analysis with respect to adult evidence

Outcomes in Children with Provoked Venous Thrombosis and Antiphospholipid Antibodies: Findings from the Kids-DOTT Trial

Veno-occlusive disease in pediatric patients after hematopoietic stem cell transplantation: relevance of activated coagulation and fibrinolysis markers and natural anticoagulants

Associations Between Clinical Factors and Postoperative Thrombosis in Pediatric Cardiac Surgery Patients: A Single-Center Retrospective Study

TGFβ1 plasma levels and clot lysis assay to better characterize patients after a first unprovoked episode of pulmonary embolism

Predictive value of D-dimer test for recurrent venous thromboembolism after anticoagulation withdrawal in subjects with a previous idiopathic event and in carriers of congenital thrombophilia

The Relationship Between D-Dimer Level, Venous Valvular Reflux and Development of the Post-Thrombotic Syndrome after Deep Venous Thrombosis.

Incidence, risk factors, and treatment patterns for deep venous thrombosis in hospitalized children: an increasing population at risk

Secondary Anticoagulation Use in Patients

D-dimer level correlation with treatment response in children with venous malformations

Duration of anticoagulation for venous thromboembolism in pediatric patients: Evaluation of the Duration of Therapy for Thrombosis in Children (Kids-DOTT) trial outcomes at 2 years

Gut Microbiota Dysbiosis and Elevated Lipopolysaccharide Serum Levels Are Associated with Venous Thromboembolism in Pediatric Patients

Model-Guided Decision-Making for Thromboprophylaxis and Hospital-Acquired Thromboembolic Events Among Hospitalized Children and Adolescents: The CLOT Randomized Clinical Trial

Assessment of the CLOT (Children's Likelihood of Thrombosis) Real-Time Risk Prediction Model of Hospital-Associated Venous Thromboembolism in Children with Congenital Heart Disease

Role of factor VIII, IX, and XI in venous thrombosis recurrence risk in adults and children: A systematic review

Global coagulation assays detect an early prothrombotic state in children with acute lymphoblastic leukemia

Children and young adults hospitalized for severe COVID-19 exhibit thrombotic coagulopathy

Hypofibrinolysis in pediatric patients with veno-occlusive disease in hematopoietic stem cell transplantation